Although the development and clinical application of SARS-CoV-2 vaccines during the
COVID-19 pandemic demonstrated unprecedented vaccine success in a short time frame, it …

Nipah virus causes highly lethal disease, with case-fatality rates ranging from 40% to 100%
in recognised outbreaks. No treatments or licensed vaccines are currently available for the …

Effective pandemic preparedness relies on anticipating viral mutations that are able to
evade host immune responses to facilitate vaccine and therapeutic design. However, current …

Nipah virus (NiV) and Hendra virus (HeV) are highly pathogenic zoonotic henipaviruses
(HNVs) responsible for recurrent outbreaks of encephalitis and respiratory illness. As the …

Highlights•Summary of the basic principles of structure-based vaccine design.•Review of
recent advances (the years 2019–2021) in structure-based vaccine design.•Preview of …

Measles virus (MeV) presents a public health threat that is escalating as vaccine coverage in
the general population declines and as populations of immunocompromised individuals …

Langya virus (LayV) is a recently discovered henipavirus (HNV), isolated from febrile
patients in China. HNV entry into host cells is mediated by the attachment (G) and fusion (F) …

We identified and isolated a novel Hendra virus (HeV) variant not detected by routine testing
from a horse in Queensland, Australia, that died from acute illness with signs consistent with …

In August 2022, a novel henipavirus (HNV) named Langya virus (LayV) was isolated from
patients with severe pneumonic disease in China. This virus is closely related to Mòjiāng …

No licensed vaccines or therapies exist for patients infected with Nipah virus (NiV), although
an experimental human monoclonal antibody (mAb) cross-reactive to the NiV and Hendra …